培美曲塞治療非小細胞肺癌術后患者致皮膚色素沉著一例_West China Medical Journal

Authors：

龔巧燕 ,  徐珽

Corresponding?author：

徐珽, Email: tingx2009@163.com

Keywords：

培美曲塞; 不良反應; 皮膚色素沉著

DOI：

10.7507/1002-0179.201702183

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 龔巧燕, 徐珽. 培美曲塞治療非小細胞肺癌術后患者致皮膚色素沉著一例. West China Medical Journal, 2017, 32(12): 2020-2021. doi: 10.7507/1002-0179.201702183 Copy

1.	Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21): 3543-3551.
2.	Schallier D, Decoster L, De Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res, 2011, 31(5): 1753-1755.
3.	Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett, 2011, 2(5): 769-772.
4.	Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na?ve patients with advanced non-small-cell lung cancer. Ann Oncol, 2002, 13(5): 737-741.
5.	Buchinger K, Stahel R, Niggemeier V, et al. Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma. Lung Cancer, 2013, 80(3): 347-349.
6.	袁曉榮, 孟令茹, 于煥欣, 等. 培美曲塞治療后致皮膚色素沉著 1 例. 臨床薈萃, 2015, 30(4): 443-444.
7.	趙元鵬, 李鳳蘭. 培美曲塞化療后皮膚色素沉著 1 例. 臨床腫瘤學雜志, 2013, 18(6): 575-576.
8.	National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. (2009-05-28)[2017-11-03]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

1. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21): 3543-3551.
2. Schallier D, Decoster L, De Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res, 2011, 31(5): 1753-1755.
3. Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett, 2011, 2(5): 769-772.
4. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na?ve patients with advanced non-small-cell lung cancer. Ann Oncol, 2002, 13(5): 737-741.
5. Buchinger K, Stahel R, Niggemeier V, et al. Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma. Lung Cancer, 2013, 80(3): 347-349.
6. 袁曉榮, 孟令茹, 于煥欣, 等. 培美曲塞治療后致皮膚色素沉著 1 例. 臨床薈萃, 2015, 30(4): 443-444.
7. 趙元鵬, 李鳳蘭. 培美曲塞化療后皮膚色素沉著 1 例. 臨床腫瘤學雜志, 2013, 18(6): 575-576.
8. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. (2009-05-28)[2017-11-03]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.